All Stories

  1. The off-label use of psychotropic medicines in paediatric patients in Australian primary care
  2. Call to collaborate on data science for older people across Europe: an EuGMS Big Data Special Interest Group position paper
  3. Rethinking anticholinergic burden in older adults: innovative approaches to detection and management
  4. Potentially inappropriate polypharmacy is an important predictor of 30-day emergency hospitalisation in older adults: a machine learning feature validation study
  5. Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties
  6. Drug Burden Index Is a Modifiable Predictor of 30-Day Hospitalization in Community-Dwelling Older Adults With Complex Care Needs: Machine Learning Analysis of InterRAI Data
  7. The Drug Burden Index and Level of Frailty as Determinants of Healthcare Costs in a Cohort of Older Frail Adults in New Zealand
  8. Investigating Variations in Medicine Approvals for Attention-Deficit/Hyperactivity Disorder: A Cross-Country Document Analysis Comparing Drug Labeling
  9. Antibiotic-Associated Acute Kidney Injury Among Older Adults: A Case-Crossover Study
  10. Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine
  11. FIP Brisbane 2023: Pharmacy Practice Research
  12. Application of machine learning approaches in predicting clinical outcomes in older adults – a systematic review and meta-analysis
  13. Data-driven digital health technologies in the remote clinical care of diabetic foot ulcers: a scoping review
  14. Post Hoc Analyses of a Randomized Controlled Trial for the Effect of Pharmacist Deprescribing Intervention on the Anticholinergic Burden in Frail Community-Dwelling Older Adults
  15. Utility of Big Data to Explore Medication Adherence in Māori and Non-Māori Community-Dwelling Older Adults with Heart Failure in Aotearoa New Zealand: A Cross-sectional Study
  16. Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review
  17. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system
  18. The association between anticholinergic burden and mobility: a systematic review and meta-analyses
  19. Antibiotic-associated acute kidney injury among older adults: A case-crossover study
  20. Deprescribing Anticholinergic and Sedative Drugs to Reduce Polypharmacy in Frail Older Adults Living in the Community: A Randomized Controlled Trial
  21. Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system
  22. Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy
  23. Rates of psychotropic medicine prescribing in paediatric populations in Australian general practice from 2000-2016
  24. Application of machine learning approaches in predicting clinical outcomes in older adults – a systematic review and meta-analysis.
  25. The association between anticholinergic burden and mobility: A systematic review and meta-analyses
  26. Development and validation of a frailty index compatible with three interRAI assessment instruments
  27. An Updated Analysis of Psychotropic Medicine Utilisation in Older People in New Zealand from 2005 to 2019
  28. Antibacterial‐associated acute kidney injury among older adults: A post‐marketing surveillance study using the FDA adverse events reporting system
  29. POS1411 ARTIFICIAL INTELLIGENCE FOR IDENTIFYING NEW DISEASE CLUSTERS IN PATIENTS WITH PSORIATIC ARTHRITIS/PSORIASIS: A PROOF-OF-CONCEPT STUDY
  30. Risk of delirium associated with antimuscarinics in older adults: A case‐time‐control study
  31. Antimicrobial-associated organ injury among the elderly: a systematic review and meta-analysis protocol
  32. Deprescribing to reduce polypharmacy: study protocol for a randomised controlled trial assessing deprescribing of anticholinergic and sedative drugs in a cohort of frail older people living in the community
  33. Risk of antimicrobial-associated organ injury among the older adults: a systematic review and meta-analysis
  34. Identifying frequent drug combinations associated with delirium in older adults: Application of association rules method to a case‐time‐control design
  35. Deprescribing To Reduce Polypharmacy: Study Protocol For A Randomised Controlled Trial Assessing Deprescribing of Anticholinergic and Sedative Drugs In A Cohort of Frail Older People Living In The Community
  36. Antimicrobial-associated Organ Injury among the Older Adults: A Systematic Review and Meta-Analysis
  37. An International Comparison of the Information in the Regulatory-Approved Drug Labeling and Prescribing Guidelines for Pediatric Depression
  38. Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults
  39. Predictors of Residential Care Admission in Community-Dwelling Older People With Dementia
  40. Antimicrobial-associated Organ Injury Among Older Adults: A Systematic Review and Meta-analyses Protocol
  41. Frailty of Māori, Pasifika, and Non-Māori/Non-Pasifika Older People in New Zealand: A National Population Study of Older People Referred for Home Care Services
  42. Impact of Anticholinergic Burden on Cognitive Performance: A Cohort Study of Community-Dwelling Older Adults
  43. Safety of fluoxetine use in children and adolescents: a disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database
  44. Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults‐a propensity score matched cohort study
  45. A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
  46. Identifying drug combinations associated with acute kidney injury using association rules method
  47. ESTABLISHING GUIDELINES FOR ALTERNATIVES TO ANTICHOLINERGIC MEDICATIONS IN OLDER ADULTS WITH DEMENTIA
  48. Reducing Potentially Inappropriate Medications in Older Adults: A Way Forward
  49. Examining the Risks of Major Bleeding Events in Older People Using Antithrombotics
  50. DEFEAT-polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities
  51. Factors associated with inappropriate prescribing among older adults with complex care needs who have undergone the interRAI assessment
  52. Determinants of prescribing potentially inappropriate medications in a nationwide cohort of community dwellers with dementia receiving a comprehensive geriatric assessment
  53. Pharmaceutical Care in Australia and New Zealand
  54. The impact of residential medication management reviews (RMMRs) on medication regimen complexity
  55. Abstract
  56. Drug burden index and its association with hip fracture among older adults: a national population-based study
  57. Association rules method and big data: Evaluating frequent medication combinations associated with fractures in older adults
  58. A systematic review evaluating the use of the interRAI home care instrument in research for older people
  59. Population-based study examining the utilization of preventive medicines by older people in the last year of life
  60. Potentially inappropriate medications in community-dwelling older adults undertaken as a comprehensive geriatric risk assessment
  61. Impact of medication reviews on inappropriate prescribing in aged care
  62. Drug Burden and its Association with Falls Among Older Adults in New Zealand: A National Population Cross-Sectional Study
  63. A population-level study examining discontinuation of statins in older people with dementia
  64. Do Residents Need All Their Medications? A Cross-Sectional Survey of RNs' Views on Deprescribing and the Role of Clinical Pharmacists
  65. Evaluation of the National Minimum Data Set for Neurological Conditions in Older Adults
  66. Development and validation of a Medicines Comorbidity Index for older people
  67. Discontinuation of Preventive Medicines in Older People with Limited Life Expectancy: A Systematic Review
  68. International trends in antipsychotic use: A study in 16 countries, 2005–2014
  69. CAN DEPRESCRIBING GIVE WHAT POLYPHARMACY HAS TAKEN AWAY? FEASIBILITY TRIAL IN RESIDENTIAL AGED CARE
  70. DO MY PATIENTS NEED ALL THEIR MEDICINES? REGISTERED NURSES’ VIEWS ON DEPRESCRIBING
  71. International trends in clozapine use: a study in 17 countries
  72. Abstracts
  73. Deprescribing anticholinergic and sedative medicines: protocol for a Feasibility Trial (DEFEAT-polypharmacy) in residential aged care facilities
  74. New Zealand's interRAI: A Resource For Examining Health Outcomes in Geriatric Pharmacoepidemiology
  75. Zopiclone Use and Risk of Fractures in Older People: Population-Based Study
  76. GLUCOSE MONITORING IN NEW USERS OF SECOND-GENERATION ANTIPSYCHOTICS IN OLDER PEOPLE
  77. Exploring New Zealand prescription data using sequence symmetry analyses for predicting adverse drug reactions
  78. Decade-long temporal trends in the utilization of preventive medicines by centenarians
  79. Adverse Drug Reactions Associated With Cholinesterase Inhibitors—Sequence Symmetry Analyses Using Prescription Claims Data
  80. Real-world risk of diabetes with antipsychotic use in older New Zealanders: a case-crossover study
  81. Cognitive adverse effects and brain deterioration associated with use of anticholinergic activity medicines in older adults
  82. Time-to-First Discontinuation, Adherence and Persistence in New Users of Second-Generation Antipsychotics
  83. A systematic review and meta-analysis on serum anticholinergic activity and adverse outcomes in older people
  84. Temporal trends in the use of antidiabetic medicines: a nationwide 9-year study in older people living in New Zealand
  85. Antihypertensive medicines utilization: A decade-long nationwide study of octogenarians, nonagenarians and centenarians
  86. An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice
  87. Temporal trends for donepezil utilization among older people
  88. Challenges and Enablers of Deprescribing: A General Practitioner Perspective
  89. Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk
  90. Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research
  91. Discontinuation of statins in a population of older New Zealanders with limited life expectancy
  92. Antiepileptic medicine utilization in older people over a 9-year study period
  93. Anticholinergics: theoretical and clinical overview
  94. Serum Anticholinergic Activity and Cognitive and Functional Adverse Outcomes in Older People: A Systematic Review and Meta-Analysis of the Literature
  95. Geographic variation in psychotropic drug utilisation among older people in New Zealand
  96. General practitioners’ insight into deprescribing for the multimorbid older individual: a qualitative study
  97. BMC Geriatrics reviewer acknowledgement 2015
  98. Examining potentially inappropriate prescribing in residential care using the STOPP/START criteria
  99. The Influence of Patient Characteristics on Anticholinergic Events in Older People
  100. ‘Real-world’ haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand
  101. Temporal trends in the utilisation of preventive medicines by older people: A 9-year population-based study
  102. Quality use of antipsychotic medicines inresidential aged care facilities in New Zealand
  103. Donepezil Adherence, Persistence and Time to First Discontinuation in a Three-Year Follow-Up of Older People
  104. Impact of residential medication management reviews on anticholinergic burden in aged care residents
  105. Proton pump inhibitors utilisation in older people in New Zealand from 2005 to 2013
  106. Analgesic Medicine Utilization in Older People in New Zealand from 2005 to 2013
  107. Credentials for a PharmD graduate: The voyage never ends
  108. Prevalence of potentially inappropriate medicine use in older New Zealanders: a population-level study using the updated 2012 Beers criteria
  109. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review
  110. Associations of Potentially Inappropriate Medicine Use with Fall-Related Hospitalisations and Primary Care Visits in Older New Zealanders: A Population-Level Study Using the Updated 2012 Beers Criteria
  111. Comparison of Anticholinergic Risk Scales and Associations with Adverse Health Outcomes in Older People
  112. Temporal Trends in Polypharmacy and Hyperpolypharmacy in Older New Zealanders over a 9-Year Period: 2005-2013
  113. Abstracts
  114. Psychotropic Medicine Utilization in Older People in New Zealand from 2005 to 2013
  115. Impact of the Pharmacist Medication Review Services on Drug-Related Problems and Potentially Inappropriate Prescribing of Renally Cleared Medications in Residents of Aged Care Facilities
  116. The impact of focused teaching sessions on New Zealand pharmacy students’ attitudes to people suffering from schizophrenia and other mental illnesses
  117. Associations of drug burden index with falls, general practitioner visits, and mortality in older people
  118. Impact of Anticholinergic Discontinuation on Cognitive Outcomes in Older People: A Systematic Review
  119. Older people's perceptions of prescription medicine costs and related costs: a pilot study in New Zealand
  120. Anticholinergic Component of the Drug Burden Index and the Anticholinergic Drug Scale as Measures of Anticholinergic Exposure in Older People in New Zealand: A Population-Level Study
  121. Potentially inappropriate medicines in a cohort of community-dwelling older people in New Zealand
  122. A retrospective study of drug-related problems in Australian aged care homes: medication reviews involving pharmacists and general practitioners
  123. Determinants of antipsychotic medication use among older people living in aged care homes in Australia
  124. Drug Burden Index and Potentially Inappropriate Medications in Community-Dwelling Older People
  125. Anticholinergic Activity of Commonly Prescribed Medications and Neuropsychiatric Adverse Events in Older People
  126. Impact of Residential Medication Management Reviews on Drug Burden Index in Aged-Care Homes
  127. Determinants of antidepressant medication prescribing in elderly residents of aged care homes in Australia: A retrospective study
  128. Psychotropic Prescribing in Long-Term Care Facilities: Impact of Medication Reviews and Educational Interventions
  129. Response to Dr. Prasad